GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Return-on-Tangible-Asset

PhaseRx (PhaseRx) Return-on-Tangible-Asset : -144.32% (As of Sep. 2017)


View and export this data going back to 2016. Start your Free Trial

What is PhaseRx Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. PhaseRx's annualized Net Income for the quarter that ended in Sep. 2017 was $-11.00 Mil. PhaseRx's average total tangible assets for the quarter that ended in Sep. 2017 was $7.62 Mil. Therefore, PhaseRx's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2017 was -144.32%.

The historical rank and industry rank for PhaseRx's Return-on-Tangible-Asset or its related term are showing as below:

PZRXQ's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -39.375
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

PhaseRx Return-on-Tangible-Asset Historical Data

The historical data trend for PhaseRx's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseRx Return-on-Tangible-Asset Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
Return-on-Tangible-Asset
-257.58 -224.46 -197.79

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -64.69 -77.71 -112.46 -128.10 -144.32

Competitive Comparison of PhaseRx's Return-on-Tangible-Asset

For the Biotechnology subindustry, PhaseRx's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhaseRx's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseRx's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where PhaseRx's Return-on-Tangible-Asset falls into.



PhaseRx Return-on-Tangible-Asset Calculation

PhaseRx's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2016 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=-20.137/( (3.914+16.448)/ 2 )
=-20.137/10.181
=-197.79 %

PhaseRx's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2017 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2017 )  (Q: Jun. 2017 )(Q: Sep. 2017 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2017 )  (Q: Jun. 2017 )(Q: Sep. 2017 )
=-11/( (9.206+6.038)/ 2 )
=-11/7.622
=-144.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2017) net income data.


PhaseRx  (OTCPK:PZRXQ) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


PhaseRx Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of PhaseRx's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseRx (PhaseRx) Business Description

Traded in Other Exchanges
N/A
Address
410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Executives
Gordon Brandt officer: Chief Medical Officer 410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr director 300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio 10-13-2017

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm 05-24-2016